<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536143</url>
  </required_header>
  <id_info>
    <org_study_id>KB103-001</org_study_id>
    <nct_id>NCT03536143</nct_id>
  </id_info>
  <brief_title>Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa</brief_title>
  <acronym>GEM-1</acronym>
  <official_title>A Phase II Study of Beremagene Geperpavec (KB103), a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krystal Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krystal Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if topical Beremagene Geperpavec (KB103,
      HSV1-COL7) can safely and effectively promote healing of DEB patient wounds (primary
      endpoint) and to assess change from baseline in Investigator Global Assessments and Patient
      Reported Outcomes (secondary endpoint).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four subjects are planned for the Phase II portion of this study: 2 adults and 2 subjects age
      5 and older. Subjects are enrolled upon obtaining consent and meeting entry criteria. Three
      wounds are selected per subject; two will receive bercolagene telserpavec and one will
      receive placebo. Administrations occur daily on Days 1 through 5, and again on Days 30, 60,
      and 90 if there is visible wound at the original administration site. Throughout the study
      wounds will imaged and biopsied for safety and efficacy analyses. Subjects will be on-trial
      for approximately 6 months: 3 months of on-site visits followed by a 3-month at-home imaging
      period.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Closure</measure>
    <time_frame>24 weeks post treatment</time_frame>
    <description>Change of wound surface area relative to baseline and placebo, time to wound closure relative to placebo, and duration of wound closure relative to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Change from baseline in the Investigator's Global Assessment score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Change from baseline in PRO scales of severity and pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of collagen VII</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Level of collagen VII in KB103-administered skin as measured by immunofluorescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anchoring fibrils</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Presence of anchoring fibrils as measured by immunoelectron microscopy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Topical beremagene geperpavec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV1-COL7A1 vector (KB103)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Topical beremagene geperpavec</intervention_name>
    <description>Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein</description>
    <arm_group_label>Topical beremagene geperpavec</arm_group_label>
    <other_name>HSV1-COL7A1</other_name>
    <other_name>KB103</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of the recessive form of dystrophic epidermolysis bullosa.

          -  Age

               1. 2 subjects: 18 years old or older,

               2. 2 subjects: 5 years old or older.

          -  At least one wound that is between 10 and 20 cm2 in wound area.

          -  Subjects, who are, in the opinion of the Investigator, able to understand the study,
             co-operate with the study procedures and are willing to return to the clinic for all
             the required follow-up visit

        Exclusion Criteria:

          -  The presence of medical illness expected to complicate participation

          -  Serum antibodies to type collagen VII

          -  Active infection in the area that will undergo injection.

          -  Evidence of systemic infection.

          -  Current evidence or a history of squamous cell carcinoma in the area that will undergo
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bullosa</keyword>
  <keyword>DEB</keyword>
  <keyword>RDEB</keyword>
  <keyword>Krystal</keyword>
  <keyword>epidermolysis</keyword>
  <keyword>Beremagene</keyword>
  <keyword>Geperpavec</keyword>
  <keyword>KB103</keyword>
  <keyword>HSV-COL7A1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

